clinical trial · NCT05737199
Assessment of the Efficacy and Safety of Pembrolizumab for Ovarian Squamous Cell Carcinoma
Niigata University Medical & Dental Hospital·phase2·active not recruiting·n = 21
Ovarian Squamous Cell CarcinomaMK-3475 (pembrolizumab)
brief summary
This is a phase II, non-randomized, open-label, single-arm, multicenter study to evaluate the efficacy and safety of MK-3475 in patients with ovarian squamous cell carcinoma.
started
May 1, 2023
primary completion
May 31, 2028
completion
May 31, 2028
last updated
Feb 5, 2026
detailed description
This study includes female patients 18 years of age or older with advanced or recurrent unresectable squamous cell carcinoma of the ovary.
Pembrolizumab will be given for a maximum of 2 years i.e. a total of 35 cycles of pembrolizumab with the q3 week dosing.
official title
A Single-arm Open-label Phase II Trial to Assess the Efficacy and Safety of Pembrolizumab for Unresectable Advanced or Recurrent Ovarian Squamous Cell Carcinoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol